DANYELZA J Code: J9348

Drug & Product Overview

HCPCS Descriptor Injection, naxitamab-gqgk, 1 mg

HCPCS Added Date July 1, 2021

Manufacturer Y-mabs Therapeutics

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About DANYELZA

Danyelza is a medication aligned to the HCPCS J Code: J9348 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravenous route and manufactured by Y-mabs Therapeutics.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
73042-0201-01	Danyelza	Y-mAbs Therapeutics, Inc.	40	40 MG / 10 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

DANYELZA Pricing & Reimbursement

J9348 Private Payer Reimbursement

$711.93 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

DANYELZA CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Danyelza (J9348) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

DANYELZA Medically Unlikely Edits (MUE)

The most billing units of J9348 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

160 units / day

= 160 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

DANYELZA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

relapsed or refractory high-risk neuroblastoma in the bone or bone marrow

Drug Class

Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]Glycolipid Disialoganglioside-directed Antibody [EPC]

Frequently Asked Questions

Is there an available Danyelza billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for DANYELZA.

Are there any available Danyelza patient assistance programs?

DANYELZA patient assistance information can be found through Y-mabs Therapeutics. Visit Here →

Where can I find Danyelza prescribing information?

DANYELZA prescribing information can be found at the link below: Visit Here →

Where can I find Danyelza side effect information?

Information regarding DANYELZA's side effects can be found at MedlinePlus Visit Here →

Does billing DANYELZA require JZ/JW wastage modifiers?

CMS has identified DANYELZA(J9348) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.